Table 3 The pharmacokinetic profile of bisthianostat in MM patients.
Group | n | tmax | Cmax | AUC0–t | AUC0–∞ | t1/2 | CL/F | Vd/F | |
|---|---|---|---|---|---|---|---|---|---|
(h) | (μg/mL) | (h × μg/mL) | (h × μg/mL) | (h) | (L/h) | (L) | |||
Day 1 | 100 mg | 3 | 0.5 (0.5–1.0) | 0.599 (61.7%) | 2.04 (45.2%) | 2.07 (45.4%) | 4.28 (31.2%) | 51.6 (46.4%) | 314 (45.3%) |
200 mg | 3 | 0.5 (0.5–1.5) | 1.11 (29.4%) | 3.63 (22.6%) | 3.76 (20.0%) | 4.38 (15.0%) | 53.8 (18.6%) | 343 (28.2%) | |
400 mg | 2 | 2.25 (1.25-3.0) | 1.30 (14.8%) | 5.13 (12.6%) | 5.19 (13.8%) | 4.10 (41.3%) | 77.5 (13.7%) | 445 (28.4%) | |
Day 28 | 100 mg | 3 | 1.5 (1.5–3.0) | 0.544 (26.8%) | 1.67 (40.8%) | 1.77 (44.1%) | 6.30 (44.2%) | 59.8 (36.2%) | 487 (18.1%) |
200 mg | 3 | 1.0 (1.0–3.0) | 1.32 (61.5%) | 4.48 (33.2%) | 4.76 (27.5%) | 7.99 (55.4%) | 43.0 (25.0%) | 538 (72.8%) | |
400 mg | 2 | 1.0 (1.0–1.0) | 1.41 (26.4%) | 9.42 (40.6%) | 9.63 (37.5%) | 3.47 (39.2%) | 42.9 (35.5%) | 230 (69.9%) |
